112 related articles for article (PubMed ID: 28110131)
1. Marked discordance between cytogenetic/molecular and morphologic findings in a patient with chronic myeloid leukemia.
Rashidi A; Courville E
Blood Cells Mol Dis; 2017 Mar; 63():32-33. PubMed ID: 28110131
[No Abstract] [Full Text] [Related]
2. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
3. Two siblings with chronic myelogenous leukemia.
Kapsali E; Tsiara S; Christou L; Panteli A; Bourantas KL
J Exp Clin Cancer Res; 2000 Dec; 19(4):541-3. PubMed ID: 11277336
[TBL] [Abstract][Full Text] [Related]
4. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
5. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
Colla S; Sammarelli G; Voltolini S; Crugnola M; Sebastio P; Giuliani N
Haematologica; 2004 May; 89(5):611-3. PubMed ID: 15136228
[TBL] [Abstract][Full Text] [Related]
6. Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.
Stagno F; Stella S; Berretta S; Massimino M; Antolino A; Giustolisi R; Messina A; Di Raimondo F; Vigneri P
Leuk Res; 2008 Apr; 32(4):673-4. PubMed ID: 17889935
[No Abstract] [Full Text] [Related]
7. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
Ross DM; Branford S; Moore S; Hughes TP
Leukemia; 2006 Apr; 20(4):664-70. PubMed ID: 16482210
[TBL] [Abstract][Full Text] [Related]
8. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
Stock W; Yu D; Karrison T; Sher D; Stone RM; Larson RA; Bloomfield CD
Int J Oncol; 2006 May; 28(5):1099-103. PubMed ID: 16596225
[TBL] [Abstract][Full Text] [Related]
9. Chronic Myeloid Leukemia With Rare Variant b2a3 (e13a3) BCR-ABL1 Fusion.
Ha J; Cheong JW; Shin S; Lee ST; Choi JR
Ann Lab Med; 2016 May; 36(3):287-9. PubMed ID: 26915625
[No Abstract] [Full Text] [Related]
10. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
[TBL] [Abstract][Full Text] [Related]
11. Detection of BCR/ABL fusion gene in CML: a preliminary report.
Rerkamnuaychoke B; Kangwanpong D; Jootar S; Puranakanitstha C
Southeast Asian J Trop Med Public Health; 1995; 26 Suppl 1():197-200. PubMed ID: 8629106
[TBL] [Abstract][Full Text] [Related]
12. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
13. Prominent hematogone hyperplasia in BCR-ABL1-positive chronic myelogenous leukemia: mimicking recurrent B-lymphoid blast crisis.
Horna P; Pantazopoulos P; Lancet JE; Moscinski LC; Zhang L
Leuk Lymphoma; 2014 Aug; 55(8):1952-4. PubMed ID: 24304373
[No Abstract] [Full Text] [Related]
14. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
15. Concurrence of e1a2 and e19a2 BCR-ABL1 Fusion Transcripts in a Typical Case of Chronic Myeloid Leukemia.
Lee J; Kim DS; Lee HS; Choi SI; Cho YG
Ann Lab Med; 2017 Jan; 37(1):74-76. PubMed ID: 27834071
[No Abstract] [Full Text] [Related]
16. Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
Radich JP; Mauro MJ
Hematol Oncol Clin North Am; 2017 Aug; 31(4):577-587. PubMed ID: 28673389
[TBL] [Abstract][Full Text] [Related]
17. CEBPA mutation in a case of chronic myeloid leukemia presenting in myeloid blast crisis.
Yin Y; Li J; Yan W; Cheng Z; Sun N; Zhang G
Leuk Lymphoma; 2017 Mar; 58(3):708-710. PubMed ID: 27379703
[No Abstract] [Full Text] [Related]
18. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
Snyder DS; McMahon R; Cohen SR; Slovak ML
Am J Hematol; 2004 Feb; 75(2):92-5. PubMed ID: 14755375
[TBL] [Abstract][Full Text] [Related]
19. Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.
Lundán T; Juvonen V; Mueller MC; Mustjoki S; Lakkala T; Kairisto V; Hochhaus A; Knuutila S; Porkka K
Haematologica; 2008 Feb; 93(2):178-85. PubMed ID: 18223279
[TBL] [Abstract][Full Text] [Related]
20. Clinical, morphological, cytogenetic and molecular aspects of a series of Ph-negative chronic myeloid leukemias.
Aurich J; Duchayne E; Huguet-Rigal F; Bauduer F; Navarro M; Perel Y; Pris J; Caballin MR; Dastugue N
Hematol Cell Ther; 1998 Aug; 40(4):149-58. PubMed ID: 9766919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
